Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Women's College Research Institute, Women's College Hospital, Toronto, Canada.
JAMA Dermatol. 2023 Sep 1;159(9):961-969. doi: 10.1001/jamadermatol.2023.2495.
Identifying and mitigating modifiable gaps in fracture preventive care for people with relapsing-remitting conditions such as eczema, asthma, and chronic obstructive pulmonary disease who are prescribed high cumulative oral corticosteroid doses may decrease fracture-associated morbidity and mortality.
To estimate the association between different oral corticosteroid prescribing patterns and appropriate fracture preventive care, including treatment with fracture preventive care medications, among older adults with high cumulative oral corticosteroid exposure.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 65 195 participants with UK electronic medical record data from the Clinical Practice Research Datalink (January 2, 1998, to January 31, 2020) and 28 674 participants with Ontario, Canada, health administrative data from ICES (April 1, 2002, to September 30, 2020). Participants were adults 66 years or older with eczema, asthma, or chronic obstructive pulmonary disease receiving prescriptions for oral corticosteroids with cumulative prednisolone equivalent doses of 450 mg or higher within 6 months. Data were analyzed October 22, 2020, to September 6, 2022.
Participants with prescriptions crossing the 450-mg cumulative oral corticosteroid threshold in less than 90 days were classified as having high-intensity prescriptions, and participants crossing the threshold in 90 days or more as having low-intensity prescriptions. Multiple alternative exposure definitions were used in sensitivity analyses.
The primary outcome was prescribed fracture preventive care. A secondary outcome was major osteoporotic fracture. Individuals were followed up from the date they crossed the cumulative oral corticosteroid threshold until their outcome or the end of follow-up (up to 1 year after index date). Rates were calculated for fracture preventive care and fractures, and hazard ratios (HRs) were estimated from Cox proportional hazards regression models comparing high- vs low-intensity oral corticosteroid prescriptions.
In both the UK cohort of 65 195 participants (mean [IQR] age, 75 [71-81] years; 32 981 [50.6%] male) and the Ontario cohort of 28 674 participants (mean [IQR] age, 73 [69-79] years; 17 071 [59.5%] male), individuals with high-intensity oral corticosteroid prescriptions had substantially higher rates of fracture preventive care than individuals with low-intensity prescriptions (UK: 134 vs 57 per 1000 person-years; crude HR, 2.34; 95% CI, 2.19-2.51, and Ontario: 73 vs 48 per 1000 person-years; crude HR, 1.49; 95% CI, 1.29-1.72). People with high- and low-intensity oral corticosteroid prescriptions had similar rates of major osteoporotic fractures (UK: crude rates, 14 vs 13 per 1000 person-years; crude HR, 1.07; 95% CI, 0.98-1.15 and Ontario: crude rates, 20 vs 23 per 1000 person-years; crude HR, 0.87; 95% CI, 0.79-0.96). Results from sensitivity analyses suggested that reaching a high cumulative oral corticosteroid dose within a shorter time, with fewer prescriptions, or with fewer or shorter gaps between prescriptions, increased fracture preventive care prescribing.
The results of this cohort study suggest that older adults prescribed high cumulative oral corticosteroids across multiple prescriptions, or with many or long gaps between prescriptions, may be missing opportunities for fracture preventive care.
对于接受高累积口服皮质类固醇剂量处方的复发性缓解型疾病(如湿疹、哮喘和慢性阻塞性肺疾病)患者,识别和减轻骨折预防护理方面的可改变差距,可能会降低与骨折相关的发病率和死亡率。
评估不同的口服皮质类固醇处方模式与适当的骨折预防护理之间的关联,包括骨折预防护理药物的治疗,在高累积口服皮质类固醇暴露的老年患者中。
设计、地点和参与者:这项队列研究包括来自英国临床实践研究数据链接(1998 年 1 月 2 日至 2020 年 1 月 31 日)的 65195 名参与者和来自加拿大安大略省健康管理数据的 28674 名参与者(2002 年 4 月 1 日至 2020 年 9 月 30 日)。参与者为年龄在 66 岁或以上、接受累积泼尼松龙等效剂量为 450mg 或更高的口服皮质类固醇处方的成人,且在 6 个月内处方超过 450mg 累积口服皮质类固醇的阈值。数据于 2020 年 10 月 22 日分析,截至 2022 年 9 月 6 日。
在不到 90 天内越过 450mg 累积口服皮质类固醇阈值的参与者被归类为高强度处方,在 90 天或更长时间内越过阈值的参与者被归类为低强度处方。在敏感性分析中使用了多种替代暴露定义。
主要结果是规定的骨折预防护理。次要结果是主要骨质疏松性骨折。从患者越过累积口服皮质类固醇阈值之日起至出现结果或随访结束(索引日期后 1 年)对患者进行随访。计算骨折预防护理和骨折的发生率,并使用 Cox 比例风险回归模型从高与低强度口服皮质类固醇处方比较估计危险比(HR)。
在英国队列的 65195 名参与者(平均[IQR]年龄 75[71-81]岁;32981[50.6%]男性)和安大略队列的 28674 名参与者(平均[IQR]年龄 73[69-79]岁;17071[59.5%]男性)中,高强度口服皮质类固醇处方的患者骨折预防护理的发生率明显高于低强度处方的患者(英国:每 1000 人年 134 比 57;粗 HR,2.34;95%CI,2.19-2.51,安大略:每 1000 人年 73 比 48;粗 HR,1.49;95%CI,1.29-1.72)。高、低强度口服皮质类固醇处方的患者主要骨质疏松性骨折的发生率相似(英国:粗率,每 1000 人年 14 比 13;粗 HR,1.07;95%CI,0.98-1.15;安大略:粗率,每 1000 人年 20 比 23;粗 HR,0.87;95%CI,0.79-0.96)。敏感性分析结果表明,在更短的时间内达到更高的累积口服皮质类固醇剂量、处方次数更少、或处方之间的间隙更少或更长,会增加骨折预防护理的处方。
这项队列研究的结果表明,接受多次处方或多次处方之间存在较大间隙的高累积口服皮质类固醇的老年患者,可能错过了骨折预防护理的机会。